Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation
Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...
Nature1d
Why the last cases of sleeping sickness will be the hardest to eliminate
Pharmaceuticals and vector-control programmes have greatly diminished the once-widespread disease, but sustained effort will ...
GlobalData on MSN2d
EMA gives OMPD to Actuate’s pancreatic cancer therapy
Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...
Hosted on MSN3d
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
GSK plc GSK announced that the FDA has granted a Breakthrough Therapy Designation to its investigational B7-H3-targeted ...
JD Supra3d
JPM2025: Regulation of artificial intelligence: Navigating a new frontier in health care
Artificial intelligence (AI) is transforming the health care landscape, from diagnostics to drug development and clinical trials. As AI ...
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...
Actuate Therapeutics announces EMA granted OMPD to elraglusib
Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to ...